Efficacy of Certican® in Combination With Myfortic® in Renal (HUSJ1)

July 20, 2011 updated by: Hospital Universitário São José

Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic®

The primary objective is to demonstrate the superiority of everolimus plus Myfortic® plus corticosteroids following CNI withdrawal at week 16 compared to tacrolimus plus Myfortic® plus corticosteroids as measured by the change in calculated Glomerular Filtration Rate (cGFR) from baseline to month 12.

The key secondary objective is to demonstrate non-inferiority of biopsy-proved acute rejection (BPAR), graft loss, death or loss to follow-up (composite endpoint) at month 12 in patients switched to everolimus plus Myfortic® plus corticosteroids following CNI withdrawal at Week 16 compared to patients maintained on tacrolimus plus Myfortic® plus corticosteroids.

Patients will be submitted to monthly GFR determination but, for group comparison, only the GFR measured at month 12 and month 24 of renal transplantation will be used.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

1.Forty patients will be selected at 16 weeks of renal transplantation with 20 patients allocated in each study arm. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.

1.1 Study protocol

Patients of renal transplant unit at the Sao Jose University Hospital who sign the inform consent and fulfill the inclusion/exclusion criteria will be enrolled in this study.

The main population will be low-risk kidney transplant recipients defined as follow: primary transplant, patients older than 18 years old and recipients of first kidney transplantation with living donor with PRA <10%, using tacrolimus, EC-MPS, and steroids as primary immunosuppression, without delayed graft function and with stable renal function 3 months after transplantation.

Patients who fulfill the inclusion criteria and agree to participate in this study will have the CNI withdrawn and the immunosuppressive regimen will be based on everolimus.

The switch will be done as follows: patients' therapy will be replaced from CNI-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.

In parallel, the CNI dose will be reduced by 50% on day 1 and another 25% on day 7. The CNI will be withdrawn on day 14 if the target levels of everolimus are obtained. EC-MPS will be unchanged until day 14 after conversion, thereafter it will be decreased if necessary from 1440mg to 1080mg/day. The dose of EC-MPS will not be below 1080 mg/day.

Corticosteroids would be unchanged. A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation. A per-operatory biopsy at baseline will not be performed, since this is not a routine practice of the transplant center and because the patients have a low immunological risk.

1.3- Inclusion criteria

1.3.1- Men and women between 18-70 years old 1.3.2- Receptors of a first living-donor kidney allograft 1.3.3- Patients must have been on a tacrolimus+myfortic regimen for at least 2 weeks prior to randomization

1.4- Exclusion criteria

1.4.1- Patients with evidence of any acute rejection following transplantation at the time of randomization 1.4.2- GFR ≤ 35 ml/min 1.4.3- Proteinuria > 800 mg/day 1.4.4- Recipients of multiple organ transplants 1.4.5- Chronic hepatic failure 1.4.6- Asymptomatic bacteriuria 1.4.7- Creatinine ≥ 2mg/dL on CNI withdrawn time 1.4.8- Proteinuria ≥ 1g/24h on CNI withdrawn time 1.4.9- Presence of uncontrolled hypercholesterolemia (≥ 350 mg/dL, ≥ 9.1 mmol/L) 1.4.10- Hypertriglyceridemia (≥ 500 mg/dL, ≥ 5.6 mmol/L)

1.5- Statistical analysis

This is an investigational and interventional study, with two-arms, to evaluate the renal function and composite efficacy end-point after conversion of immunosuppressive regime from tacrolimus to everolimus. As this is a pilot study, the sample size was estimated with 20 patients in each arm (total = 40 patients) according to the number of kidney transplants usually performed at the hospital.

For GRF evaluation ANOVA will be used. A difference of 5-10ml/min at GRF is expected comparing study and control group.

The incidence of acute rejection will be analyzed by chi-square.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Brazil
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30140-073

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women between 18-70 years old
  • Receptors of a first living-donor kidney allograft
  • Patients must have been on a tacrolimus+myfortic regimen for at least 2 weeks prior to randomization

Exclusion Criteria:

  • Patients with evidence of any acute rejection following transplantation at the time of randomization
  • GFR ≤ 35 ml/min
  • Proteinuria > 800 mg/day
  • Recipients of multiple organ transplants
  • Chronic hepatic failure
  • Asymptomatic bacteriuria
  • Creatinine ≥ 2mg/dL on CNI withdrawn time
  • Proteinuria ≥ 1g/24h on CNI withdrawn time
  • Presence of uncontrolled hypercholesterolemia (≥ 350 mg/dL, ≥ 9.1 mmol/L)
  • Hypertriglyceridemia (≥ 500 mg/dL, ≥ 5.6 mmol/L)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Certican, prednisona, EC-MPS
Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
Drug: Certican
Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
Other Names:
  • Myfortic, Prograf, Certican.
No Intervention: Tacrolimus,Prednisona, EC-MPS
Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glomerular Filtration Rate
Time Frame: 96 weeks
The primary objective is to demonstrate the superiority of everolimus plus Myfortic® plus corticosteroids following CNI withdrawal at week 16 compared to tacrolimus plus Myfortic® plus corticosteroids as measured by the change in calculated Glomerular Filtration Rate (cGFR) from baseline to month 12.
96 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-inferiority of biopsy-proved acute rejection (BPAR), graft loss, death
Time Frame: 1 year after enrollment
The key secondary objective is to demonstrate non-inferiority of biopsy-proved acute rejection (BPAR), graft loss, death or loss to follow-up (composite endpoint) at month 12 in patients switched to everolimus plus Myfortic® plus corticosteroids following CNI withdrawal at Week 16 compared to patients maintained on tacrolimus plus Myfortic® plus corticosteroids.
1 year after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Universitário São José

Investigators

  • Study Director: Euler P lasmar, Hospital Universitario Sao Jose

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Anticipated)

June 1, 2012

Study Completion (Anticipated)

June 1, 2013

Study Registration Dates

First Submitted

June 20, 2011

First Submitted That Met QC Criteria

July 20, 2011

First Posted (Estimate)

July 21, 2011

Study Record Updates

Last Update Posted (Estimate)

July 21, 2011

Last Update Submitted That Met QC Criteria

July 20, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EL-1254

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disorder Related to Renal Transplantation

Clinical Trials on Certican

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe